Free CME from PeerView

Continuing Nursing Education (CNE) Activities

The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
StartThis activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
StartThis activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
StartThis activity expired on November 26, 2024; credit is no longer available.
Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
Activity Description and Educational Objectives
For people with obesity, early intervention is central to reducing the
risk for related comorbidities. However, almost half of these people are
never formally diagnosed, nor do they ever receive care specifically
targeting their obesity. But why? Obesity can be challenging to discuss with
patients due to clinician discomfort or uncertainty, lack of training, or
personal biases. For these reasons and more, there is no denying that
managing obesity is complex. Characterizing obesity as a chronic disease
resulting from metabolic adaptation rather than a personal failing means we
can reframe how we approach its treatment.
This latest educational opportunity on obesity from PeerView, developed in
collaboration with the University of Florida College of Medicine, teaches
primary care providers how to practice what they preach and inspire change.
By the end of this activity, you will have gained knowledge to prioritize
obesity management in the primary care setting, learn strategies to
effectively discuss anti-obesity medications, and get expert tools to modify
obesity management plans to meet individual long-term goals. This informative
activity features expert faculty, a video segment depicting patient-provider
conversations (thanks to skilled actors with the University of Delaware
Healthcare Theater Program), and the latest on practical skills and clinical
data.
Upon completion of this activity, participants should be better able to:
- Initiate nonbiased discussions with patients early in the course of obesity to establish and achieve realistic weight loss goals to prevent the development and progression of obesity-related comorbidities
- Evaluate the mechanisms of action, efficacy, and safety of anti-obesity medications as adjunctive treatment to support behavior and lifestyle efforts towards achieving and maintaining weight loss over the long term and to minimize the impact of obesity-related comorbidities
- Personalize treatment plans to avoid or minimize comorbidities and optimize long-term outcomes for people with obesity consistent with current guideline recommendations, available evidence, and according to shared decision-making principles
Target Audience
This activity has been designed to meet the educational needs of US-based primary care providers including physicians, NPs, PAs, and other healthcare professionals involved in the care of people with obesity.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME credit and 75% or higher to obtain NCPD credit. There
are no prerequisites and there is no fee to participate in this activity or
to receive CME/NCPD/AAPA credit. Statements of Credit are awarded upon
successful completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: November 27, 2023 - November 26, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Co-Chair & Presenter
W. Troy Donahoo, MD, FTOS
Professor and Chief
Division of Endocrinology, Diabetes & Metabolism
Department of Medicine
University of Florida
Gainesville, Florida
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair & Presenter
Amy J. Sheer, MD, MPH
Assistant Professor of Medicine
Diplomat of the American Board of Obesity Medicine
Department of Medicine
Division of Internal Medicine
University of Florida College of Medicine
Gainesville, Florida
Amy J. Sheer, MD, MPH, has no financial interests/relationships or
affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Patient Actor
Gerre Garrett Pierce
Actors of Health Care Theatre have nothing to disclose.
Medical Directors
Angela McIntosh, PhD
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Margery Tamas, MPH
Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support



The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Partners
Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
Activity Description and Educational Objectives
For people with obesity, early intervention is central to reducing the
risk for related comorbidities. However, almost half of these people are
never formally diagnosed, nor do they ever receive care specifically
targeting their obesity. But why? Obesity can be challenging to discuss with
patients due to clinician discomfort or uncertainty, lack of training, or
personal biases. For these reasons and more, there is no denying that
managing obesity is complex. Characterizing obesity as a chronic disease
resulting from metabolic adaptation rather than a personal failing means we
can reframe how we approach its treatment.
This latest educational opportunity on obesity from PeerView, developed in
collaboration with the University of Florida College of Medicine, teaches
primary care providers how to practice what they preach and inspire change.
By the end of this activity, you will have gained knowledge to prioritize
obesity management in the primary care setting, learn strategies to
effectively discuss anti-obesity medications, and get expert tools to modify
obesity management plans to meet individual long-term goals. This informative
activity features expert faculty, a video segment depicting patient-provider
conversations (thanks to skilled actors with the University of Delaware
Healthcare Theater Program), and the latest on practical skills and clinical
data.
Upon completion of this activity, participants should be better able to:
- Initiate nonbiased discussions with patients early in the course of obesity to establish and achieve realistic weight loss goals to prevent the development and progression of obesity-related comorbidities
- Evaluate the mechanisms of action, efficacy, and safety of anti-obesity medications as adjunctive treatment to support behavior and lifestyle efforts towards achieving and maintaining weight loss over the long term and to minimize the impact of obesity-related comorbidities
- Personalize treatment plans to avoid or minimize comorbidities and optimize long-term outcomes for people with obesity consistent with current guideline recommendations, available evidence, and according to shared decision-making principles
Target Audience
This activity has been designed to meet the educational needs of US-based primary care providers including physicians, NPs, PAs, and other healthcare professionals involved in the care of people with obesity.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME credit and 75% or higher to obtain NCPD credit. There
are no prerequisites and there is no fee to participate in this activity or
to receive CME/NCPD/AAPA credit. Statements of Credit are awarded upon
successful completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: November 27, 2023 - November 26, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Co-Chair & Presenter
W. Troy Donahoo, MD, FTOS
Professor and Chief
Division of Endocrinology, Diabetes & Metabolism
Department of Medicine
University of Florida
Gainesville, Florida
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair & Presenter
Amy J. Sheer, MD, MPH
Assistant Professor of Medicine
Diplomat of the American Board of Obesity Medicine
Department of Medicine
Division of Internal Medicine
University of Florida College of Medicine
Gainesville, Florida
Amy J. Sheer, MD, MPH, has no financial interests/relationships or
affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Patient Actor
Gerre Garrett Pierce
Actors of Health Care Theatre have nothing to disclose.
Medical Directors
Angela McIntosh, PhD
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Margery Tamas, MPH
Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support



The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Partners
Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
StartThis activity expired on November 12, 2024; credit is no longer available.
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
Media: Enduring Material
Activity Release Date: November 13, 2023
Activity Expiration Date: November 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, experts discuss the underlying pathophysiology involved in the development of plaque psoriasis, focusing on IL-23 signaling and the targeting of the TYK2 kinase, and patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as well as personalized management plans for patients with psoriasis.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other healthcare professionals involved in the care of patients with psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the underlying pathophysiology involved in the development of plaque psoriasis, specifically focusing on IL-23 signaling and the selective targeting of the TYK2 kinase
- Select patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as supported by the latest efficacy and safety data
- Formulate personalized management plans for patients with psoriasis utilizing a team approach while addressing individuals’ treatment goals and preferences as well as inequities and disparities in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California, Los Angeles (UCLA)
Los Angeles, California
April W. Armstrong, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira,
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical;
Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals;
Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant
Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi;
and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer;
Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until . PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 12, 2024; credit is no longer available.
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
Media: Enduring Material
Activity Release Date: November 13, 2023
Activity Expiration Date: November 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, experts discuss the underlying pathophysiology involved in the development of plaque psoriasis, focusing on IL-23 signaling and the targeting of the TYK2 kinase, and patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as well as personalized management plans for patients with psoriasis.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other healthcare professionals involved in the care of patients with psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the underlying pathophysiology involved in the development of plaque psoriasis, specifically focusing on IL-23 signaling and the selective targeting of the TYK2 kinase
- Select patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as supported by the latest efficacy and safety data
- Formulate personalized management plans for patients with psoriasis utilizing a team approach while addressing individuals’ treatment goals and preferences as well as inequities and disparities in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California, Los Angeles (UCLA)
Los Angeles, California
April W. Armstrong, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira,
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical;
Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals;
Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant
Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi;
and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer;
Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until . PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
StartThis activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
StartThis activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
StartThis activity expired on October 30, 2024; credit is no longer available.
Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
Media: Enduring Material
Activity Release Date: October 31, 2023
Activity Expiration Date: October 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to optimize the care of patients with small-cell lung cancer (SCLC) in the community setting with Dr. Ticiana Leal, as she reviews the latest therapeutic advances, guideline recommendations, and team-based best practices to offer practical insights on individualizing care for individuals with SCLC in your practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the characteristics, mechanisms of action, and efficacy/safety profiles of the latest therapeutic options for SCLC
- Develop individualized treatment plans for patients with SCLC based on the latest evidence-based practices, guideline recommendations, and patient needs and preferences that should inform and guide therapeutic decisions in different settings and lines of therapy
- Implement multidisciplinary and interprofessional strategies and shared decision-making to ensure the rapid, appropriate initiation of therapy and optimal care throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/30/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 30, 2024; credit is no longer available.
Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
Media: Enduring Material
Activity Release Date: October 31, 2023
Activity Expiration Date: October 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to optimize the care of patients with small-cell lung cancer (SCLC) in the community setting with Dr. Ticiana Leal, as she reviews the latest therapeutic advances, guideline recommendations, and team-based best practices to offer practical insights on individualizing care for individuals with SCLC in your practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the characteristics, mechanisms of action, and efficacy/safety profiles of the latest therapeutic options for SCLC
- Develop individualized treatment plans for patients with SCLC based on the latest evidence-based practices, guideline recommendations, and patient needs and preferences that should inform and guide therapeutic decisions in different settings and lines of therapy
- Implement multidisciplinary and interprofessional strategies and shared decision-making to ensure the rapid, appropriate initiation of therapy and optimal care throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/30/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
StartThis activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
StartThis activity expired on October 17, 2024; credit is no longer available.
Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
Media: Enduring Material
Activity Release Date: October 18, 2023
Activity Expiration Date: October 17, 2024
Time to Complete Activity: 60 minutes
Activity Description
Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other clinicians involved in the management of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction
- Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy
- Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jonathan I. Silverberg, MD, PhD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Jonathan I. Silverberg, MD, PhD, MPH, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Alamar Biosciences, Inc.;
Aldena Therapeutics; Amgen Inc.; AOBiome; Arcutis Biotherapeutics, Inc.;
Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals
Pte Ltd; BioMX; Biosion; Bodewell; Boehringer Ingelheim Pharmaceuticals,
Inc.; Cara Therapeutics; Castle Biosciences, Inc.; Celgene Corporation;
Connect Biopharma; Dermavant Sciences, Inc.; Dermira, Inc.; Dermtech;
Galderma S.A.; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; Leo Pharma;
Lilly; Menlo Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Optum,
Inc.; Pfizer; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi
Genzyme; Shaperon; and UNION therapeutics A/S.
Grant/Research Support from Galderma S.A.; Incyte; and Pfizer.
Speaker for Abbvie Inc.; Leo Pharma; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi Genzyme.
Co-Chair/Planner
Linda Stein Gold, MD
Director of Clinical Research
Department of Dermatology
Henry Ford Health
Detroit, Michigan
Division Head Dermatology
Henry Ford Health
West Bloomfield, Michigan
Linda Stein Gold, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi.
Patient Actor
Heather Mekulski
Heather Mekulski has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Gina Ostmann has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Javonte Perry
Javonte Perry has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners

This activity has been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23096339. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/17/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 17, 2024; credit is no longer available.
Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
Media: Enduring Material
Activity Release Date: October 18, 2023
Activity Expiration Date: October 17, 2024
Time to Complete Activity: 60 minutes
Activity Description
Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other clinicians involved in the management of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction
- Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy
- Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jonathan I. Silverberg, MD, PhD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Jonathan I. Silverberg, MD, PhD, MPH, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Alamar Biosciences, Inc.;
Aldena Therapeutics; Amgen Inc.; AOBiome; Arcutis Biotherapeutics, Inc.;
Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals
Pte Ltd; BioMX; Biosion; Bodewell; Boehringer Ingelheim Pharmaceuticals,
Inc.; Cara Therapeutics; Castle Biosciences, Inc.; Celgene Corporation;
Connect Biopharma; Dermavant Sciences, Inc.; Dermira, Inc.; Dermtech;
Galderma S.A.; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; Leo Pharma;
Lilly; Menlo Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Optum,
Inc.; Pfizer; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi
Genzyme; Shaperon; and UNION therapeutics A/S.
Grant/Research Support from Galderma S.A.; Incyte; and Pfizer.
Speaker for Abbvie Inc.; Leo Pharma; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi Genzyme.
Co-Chair/Planner
Linda Stein Gold, MD
Director of Clinical Research
Department of Dermatology
Henry Ford Health
Detroit, Michigan
Division Head Dermatology
Henry Ford Health
West Bloomfield, Michigan
Linda Stein Gold, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi.
Patient Actor
Heather Mekulski
Heather Mekulski has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Gina Ostmann has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Javonte Perry
Javonte Perry has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners

This activity has been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23096339. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/17/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
StartThis activity expired on October 15, 2024; credit is no longer available.
Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
Media: Enduring Material
Activity Release Date: October 16, 2023
Activity Expiration Date: October 15, 2024
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac
disease, with a mortality rate estimated to be about three times greater than
that experienced by individuals of similar age without HCM. So far, the FDA
has approved only one noninvasive treatment option indicated for the
treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called
mavacamten. A second CMI, aficamten, is currently being studied. As timely
diagnosis of patients with HCM may reduce or delay the need for invasive
treatment, these treatment options are essential for cardiologists to
understand.
This PeerView activity covers what you need to know about diagnosing and
managing HCM for optimal patient care. A patient case threads through each
section and offers a window into real-world diagnostic and treatment
challenges as our expert shares guidance and the latest evidence. By the end
of this activity, you will be able to explain the underlying pathophysiology
of HCM, apply your new knowledge for timely diagnosis and individualized
treatment of HCM, and implement strategies for long-term patient safety and
improved outcomes.
Target Audience
This activity has been designed to meet the educational needs of cardiologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the care of patients with HCM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM
- Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM
- Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities
- Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol
Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon
Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics ; and
Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/15/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 15, 2024; credit is no longer available.
Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
Media: Enduring Material
Activity Release Date: October 16, 2023
Activity Expiration Date: October 15, 2024
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac
disease, with a mortality rate estimated to be about three times greater than
that experienced by individuals of similar age without HCM. So far, the FDA
has approved only one noninvasive treatment option indicated for the
treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called
mavacamten. A second CMI, aficamten, is currently being studied. As timely
diagnosis of patients with HCM may reduce or delay the need for invasive
treatment, these treatment options are essential for cardiologists to
understand.
This PeerView activity covers what you need to know about diagnosing and
managing HCM for optimal patient care. A patient case threads through each
section and offers a window into real-world diagnostic and treatment
challenges as our expert shares guidance and the latest evidence. By the end
of this activity, you will be able to explain the underlying pathophysiology
of HCM, apply your new knowledge for timely diagnosis and individualized
treatment of HCM, and implement strategies for long-term patient safety and
improved outcomes.
Target Audience
This activity has been designed to meet the educational needs of cardiologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the care of patients with HCM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM
- Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM
- Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities
- Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol
Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon
Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics ; and
Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/15/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care
StartThis activity expired on November 11, 2024; credit is no longer available.
Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care
Media: Enduring Material
Activity Release Date: October 12, 2023
Activity Expiration Date: November 11, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of depression begins with adequate screening and early
introduction of appropriate therapy. However, monoaminergic antidepressant
therapies, which are currently considered the standard of care, have several
limitations, such as slow therapeutic response times, suboptimal efficacy and
remission rates, and adverse effects that may impact patient adherence.
Recent research has focused on novel pathways involved in the etiology of
depression, including glutamatergic and GABAergic modulation. For example,
neuroactive steroids such as zuranolone act as positive allosteric modulators
of the GABA-A receptor. In 2023, zuranolone became the first and only oral
therapy to be approved for the treatment of postpartum depression. There have
also been advances in glutamatergic antidepressants, with the approval of
esketamine nasal spray for treatment-resistant depression in 2019 and for
depression with acute suicidal ideation or behavior in 2020, as well as the
approval of dextromethorphan-bupropion for the treatment of major depressive
disorder in 2022.
In order to help clinicians remain abreast of the latest treatment options
for depression, PeerView recently held a Candid Conversations & Clinical
Consults educational symposium, featuring a panel of psychiatric–mental
health nursing faculty. These depression experts paired compelling,
real-world case scenarios with practice-changing evidence to illustrate how
to integrate novel and emerging treatments for depression into clinical
practice, including strategies to identify patients who may benefit from
these treatments, and how to use shared decision-making to craft
individualized treatment plans. If you couldn’t watch the live event, this
on-demand version is available now!
Target Audience
This activity has been designed to meet the educational needs of psychiatric-mental health nurses, including advanced practice registered nurses, clinical nurse specialists, psychiatric nurse practitioners, and other clinicians involved in the management of depression.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the mechanisms of action of novel and emerging rapid-acting treatments for depression
- Evaluate the efficacy, safety, and tolerability of novel and emerging rapid-acting treatments for depression
- Identify patients with depression who may benefit from new and emerging rapid-acting treatment options
- Engage in shared decision-making to optimize treatment selection considering the latest clinical evidence as well as the patient’s symptoms, preferences, and unmet needs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer
Board-Certified Nurse Practitioner
The Hamilton Group Behavioral Health LLC
Certified Clinical Master Psychopharmacologist
AANP Nevada State Representative
Las Vegas, Nevada
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP,
has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkermes and Point of Care Network,
LLC (POCN).
Speaker for Myriad Neuroscience and Point of Care Network, LLC
(POCN).
Co-Chair/Planner
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Associate Professor
Rasmussen University
Bloomington, Minnesota
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Point of Care Network (POCN).
Speaker for Lippincott Clinical Pulse and Practical Updates in
Primary Care.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sage Therapeutics and Biogen.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106405. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/11/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This NCPD/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 11, 2024; credit is no longer available.
Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care
Media: Enduring Material
Activity Release Date: October 12, 2023
Activity Expiration Date: November 11, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of depression begins with adequate screening and early
introduction of appropriate therapy. However, monoaminergic antidepressant
therapies, which are currently considered the standard of care, have several
limitations, such as slow therapeutic response times, suboptimal efficacy and
remission rates, and adverse effects that may impact patient adherence.
Recent research has focused on novel pathways involved in the etiology of
depression, including glutamatergic and GABAergic modulation. For example,
neuroactive steroids such as zuranolone act as positive allosteric modulators
of the GABA-A receptor. In 2023, zuranolone became the first and only oral
therapy to be approved for the treatment of postpartum depression. There have
also been advances in glutamatergic antidepressants, with the approval of
esketamine nasal spray for treatment-resistant depression in 2019 and for
depression with acute suicidal ideation or behavior in 2020, as well as the
approval of dextromethorphan-bupropion for the treatment of major depressive
disorder in 2022.
In order to help clinicians remain abreast of the latest treatment options
for depression, PeerView recently held a Candid Conversations & Clinical
Consults educational symposium, featuring a panel of psychiatric–mental
health nursing faculty. These depression experts paired compelling,
real-world case scenarios with practice-changing evidence to illustrate how
to integrate novel and emerging treatments for depression into clinical
practice, including strategies to identify patients who may benefit from
these treatments, and how to use shared decision-making to craft
individualized treatment plans. If you couldn’t watch the live event, this
on-demand version is available now!
Target Audience
This activity has been designed to meet the educational needs of psychiatric-mental health nurses, including advanced practice registered nurses, clinical nurse specialists, psychiatric nurse practitioners, and other clinicians involved in the management of depression.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the mechanisms of action of novel and emerging rapid-acting treatments for depression
- Evaluate the efficacy, safety, and tolerability of novel and emerging rapid-acting treatments for depression
- Identify patients with depression who may benefit from new and emerging rapid-acting treatment options
- Engage in shared decision-making to optimize treatment selection considering the latest clinical evidence as well as the patient’s symptoms, preferences, and unmet needs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer
Board-Certified Nurse Practitioner
The Hamilton Group Behavioral Health LLC
Certified Clinical Master Psychopharmacologist
AANP Nevada State Representative
Las Vegas, Nevada
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP,
has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkermes and Point of Care Network,
LLC (POCN).
Speaker for Myriad Neuroscience and Point of Care Network, LLC
(POCN).
Co-Chair/Planner
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Associate Professor
Rasmussen University
Bloomington, Minnesota
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Point of Care Network (POCN).
Speaker for Lippincott Clinical Pulse and Practical Updates in
Primary Care.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sage Therapeutics and Biogen.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106405. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/11/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This NCPD/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
StartThis activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond
StartThis activity expired on November 1, 2024; credit is no longer available.
Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond
Media: Enduring Material
Activity Release Date: October 2, 2023
Activity Expiration Date: November 1, 2024
Time to Complete Activity: 90 minutes
Activity Description
Despite all of the advances in cancer treatment, there is still a
significant need for a fourth pillar of therapy that can help improve
outcomes for patients across a spectrum of solid tumors, such as
glioblastoma, lung cancer, and GI malignancies. In this PeerView activity, an
expert faculty panel will review the latest cutting-edge data supporting the
use of tumor treating fields (TTFields) and synergistic combination
strategies in established and emerging solid tumor indications from CNS to
thoracic malignancies and beyond.
You'll gain strategies to maximize treatment adherence and quality of life,
develop skills for evidence-based adverse event management, and discover
life-prolonging clinical trial opportunities. Delve into the science behind
the use of TTFields in the treatment of solid malignancies, the latest
evidence on the efficacy and safety of this modality across approved and
emerging indications, and radiation oncology–focused guidance for the safe
and effective incorporation of TTFields therapy in the clinic.
Target Audience
This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanistic rationale and evidence supporting the use of TTFields for the treatment of patients with CNS, thoracic, and other aggressive solid tumors
- Integrate TTFields into multimodal management protocols for appropriately selected patients with CNS, thoracic, and other solid malignancies
- Devise team-based strategies designed to mitigate and manage adverse events associated with TTFields to improve outcomes in patients with difficult-to-treat cancers
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erik P. Sulman, MD, PhD
Assistant Dean for Physicians Scientist Education
Professor and Vice-Chair of Research
Department of Radiation Oncology
Co-Director, Brain and Spine Tumor Center
Laura and Isaac Perlmutter Cancer Center
Director, Medical Scientist (MD/PhD) Training Program
NYU Grossman School of Medicine
New York, New York
Erik P. Sulman, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Novocure, Inc.
Grant/Research Support from Novocure, Inc.
Faculty/Planner
Zachary D. Horne, MD
Division of Radiation Oncology
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
Zachary D. Horne, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Novocure, Inc.
Faculty/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 11/1/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 1, 2024; credit is no longer available.
Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond
Media: Enduring Material
Activity Release Date: October 2, 2023
Activity Expiration Date: November 1, 2024
Time to Complete Activity: 90 minutes
Activity Description
Despite all of the advances in cancer treatment, there is still a
significant need for a fourth pillar of therapy that can help improve
outcomes for patients across a spectrum of solid tumors, such as
glioblastoma, lung cancer, and GI malignancies. In this PeerView activity, an
expert faculty panel will review the latest cutting-edge data supporting the
use of tumor treating fields (TTFields) and synergistic combination
strategies in established and emerging solid tumor indications from CNS to
thoracic malignancies and beyond.
You'll gain strategies to maximize treatment adherence and quality of life,
develop skills for evidence-based adverse event management, and discover
life-prolonging clinical trial opportunities. Delve into the science behind
the use of TTFields in the treatment of solid malignancies, the latest
evidence on the efficacy and safety of this modality across approved and
emerging indications, and radiation oncology–focused guidance for the safe
and effective incorporation of TTFields therapy in the clinic.
Target Audience
This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanistic rationale and evidence supporting the use of TTFields for the treatment of patients with CNS, thoracic, and other aggressive solid tumors
- Integrate TTFields into multimodal management protocols for appropriately selected patients with CNS, thoracic, and other solid malignancies
- Devise team-based strategies designed to mitigate and manage adverse events associated with TTFields to improve outcomes in patients with difficult-to-treat cancers
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erik P. Sulman, MD, PhD
Assistant Dean for Physicians Scientist Education
Professor and Vice-Chair of Research
Department of Radiation Oncology
Co-Director, Brain and Spine Tumor Center
Laura and Isaac Perlmutter Cancer Center
Director, Medical Scientist (MD/PhD) Training Program
NYU Grossman School of Medicine
New York, New York
Erik P. Sulman, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Novocure, Inc.
Grant/Research Support from Novocure, Inc.
Faculty/Planner
Zachary D. Horne, MD
Division of Radiation Oncology
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
Zachary D. Horne, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Novocure, Inc.
Faculty/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 11/1/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
StartThis activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
StartThis activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
StartThis activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
StartThis activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
StartThis activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
StartThis activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
StartThis activity expired on September 24, 2024; credit is no longer available.
Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
Media: Enduring Material
Activity Release Date: August 25, 2023
Activity Expiration Date: September 24, 2024
Time to Complete Activity: 30 minutes
Activity Description
Atopic dermatitis (AD) is a chronic disease that affects a significant
portion of the US population. The current treatment paradigm for AD is
complex, involving multiple active drugs tailored to different body parts,
stages of the disease, and severity levels, in addition to moisturizers,
bathing practices, and lifestyle recommendations. However, the effectiveness
of certain available treatment options is limited because of concerns
regarding efficacy, tolerability, and safety. In recent years, there have
been significant advancements in the treatment of AD, including the approval
of the first biologic agent and the ongoing clinical development of targeted
therapies.
In this activity, a panel of experts discuss the severity of AD across
different patient populations, considering the chronic and heterogeneous
nature of the disease, and the underlying pathophysiologic processes that
contribute to the development of AD. In addition, they explore
individualizing treatment for patients with moderate to severe AD, with a
goal of minimizing and preventing flares.
Target Audience
This activity has been designed to meet the educational needs of dermatology nurse practitioners and physician assistants and other healthcare professionals involved in the care of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease
- Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy
- Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly;
Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi;
Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Novartis
Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun
Pharmaceutical Industries Limited; and UCB, Inc.
Co-Chair/Planner
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, Illinois
Peter A. Lio, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris,
Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s
Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.;
Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.;
Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals
Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte;
Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23086287. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/24/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 24, 2024; credit is no longer available.
Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
Media: Enduring Material
Activity Release Date: August 25, 2023
Activity Expiration Date: September 24, 2024
Time to Complete Activity: 30 minutes
Activity Description
Atopic dermatitis (AD) is a chronic disease that affects a significant
portion of the US population. The current treatment paradigm for AD is
complex, involving multiple active drugs tailored to different body parts,
stages of the disease, and severity levels, in addition to moisturizers,
bathing practices, and lifestyle recommendations. However, the effectiveness
of certain available treatment options is limited because of concerns
regarding efficacy, tolerability, and safety. In recent years, there have
been significant advancements in the treatment of AD, including the approval
of the first biologic agent and the ongoing clinical development of targeted
therapies.
In this activity, a panel of experts discuss the severity of AD across
different patient populations, considering the chronic and heterogeneous
nature of the disease, and the underlying pathophysiologic processes that
contribute to the development of AD. In addition, they explore
individualizing treatment for patients with moderate to severe AD, with a
goal of minimizing and preventing flares.
Target Audience
This activity has been designed to meet the educational needs of dermatology nurse practitioners and physician assistants and other healthcare professionals involved in the care of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease
- Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy
- Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly;
Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi;
Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Novartis
Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun
Pharmaceutical Industries Limited; and UCB, Inc.
Co-Chair/Planner
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, Illinois
Peter A. Lio, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris,
Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s
Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.;
Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.;
Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals
Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte;
Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23086287. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/24/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView